Abstract:Background: Nowadays, although the cause of hepatocellular carcinoma (HCC) mortality and recurrence remains at a high level, the 5-year survival rate is still very low. The DNA damage response and repair (DDR) pathway may affect HCC patients' survival by influencing tumor development and therapeutic response. It is necessary to identify a prognostic DDR-related gene signature to predict the outcome of patients. Methods: Level 3 mRNA expression and clinical information were extracted from the TCGA website. The GSE14520 datasets, ICGC-LIRI datasets, and a Chinese HCC cohort were served as validation sets. Univariate Cox regression analysis and LASSO-penalized Cox regression analysis were performed to construct the DDR-related gene pair (DRGP) signature. Kaplan-Meier survival curves and time-dependent receiver operating characteristic (ROC) analysis curves were calculated to determine the predictive ability of this prognostic model. Then, a prognostic nomogram was established to help clinical management. We investigated the difference in biological processes between HRisk and LRisk by conducting several enrichment analyses. The TIDE algorithm and R package "pRRophetic" were applied to estimate the immunotherapeutic and chemotherapeutic response. Results: We constructed the prognostic signature based on 23 DDR-related gene pairs. The patients in the training datasets were divided into HRisk and LRisk groups at median cut-off. The HRisk group had significantly poorer OS than the LRisk group, and the signature was an independent prognostic indicator in HCC. Furthermore, a nomogram of the riskscore combined with TNM stage was constructed and detected by the calibration curve and decision curve. The LRisk group was associated with higher expression of HBV oncoproteins and metabolism pathways, while DDR-relevant pathways and cell cycle process were enriched in the HRisk group. Moreover, patients in the LRisk group may be more beneficial from immunotherapy. We also found that TP53 gene was more frequently mutated in the HRisk group. As for chemotherapeutic drugs commonly used in HCC, the HRisk group was highly sensitive to 5-fluorouracil, while the LRisk group presented with a significantly higher response to gefitinib and gemcitabine. Conclusion: Overall, we developed a novel DDR-related gene pair signature and nomogram to assist in predicting survival outcomes and clinical treatment of HCC patients. It also helps understand the underlying mechanisms of different DDR patterns in HCC.

LOH Analysis of Genes Around D4S2964 Identifies ARD1B As a Prognostic Predictor of Hepatocellular Carcinoma.

Loss of Heterozygosity at D8S298 is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma

Loss of heterozygosity at D8S262: an early genetic event of hepatocarcinogenesis

The Roles of Loss of Heterozygosity at 8p22 in the Molecular Classification of Patients with Hepatocellular Carcinoma, with Special Reference to Survival after Surgical Operation

The value of chromosomal loss of heterozygosity in prognosis prediction of hepatocellular carcinoma patients with curative resection

The prognostic value of chromosomal loss of heterozygosity in molecular staging for TNM stage Ⅰ of hepatocellular carcinoma

[Loss of Heterozygosity of Plasma Circulating DNA from Hepatocellular Carcinoma Patients and Its Clinical Significance].

Significance of loss of heterozygosity chromosome 1 in hepatocellular carcinoma

The Association of Frequent Allelic Loss on 17p13.1 with Early Metastastic Recurrence of Hepatocellular Carcinoma after Liver Transplantation

The Prognostic Value of AT-Rich Interaction Domain (ARID) Family Members in Patients with Hepatocellular Carcinoma

Polymorphisms in Genes of the De Novo Lipogenesis Pathway and Overall Survival of Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization.

Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma

Abstract A25: Array-based Comparative Genomic Hybridization of Hepatocellular Carcinoma Reveals a Unique Genomic Aberration Pattern in Tumors with Poor Prognosis

Clinical significance of long non-coding RNA DUXAP8 and its protein coding genes in hepatocellular carcinoma

A Robust Twelve-Gene Signature for Prognosis Prediction of Hepatocellular Carcinoma

Loss of heterozygosity at chromosomal 1p36 in small hepatocellular carcinoma patients

Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma

Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma

Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma

Liver Regeneration-Related Genes of Nontumor Liver Tissues Predict the Prognosis of Patients with Hepatocellular Carcinoma

Angiogenesis-Related Immune Signatures Correlate With Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity in Hepatocellular Carcinoma